The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis

INTRODUCTION: While premenopausal patients with HR+ HER2− early breast cancer are treated with tamoxifen +/− ovarian suppression with a GnRH analog or an aromatase inhibitor (AI) + GnRH, the majority of postmenopausal women receive an AI due to its higher efficacy compared to tamoxifen. As the intro...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabieva, Naiba, Altmann, Falk, Apel, Klaus, Baerens, Dirk-Toralf, Beha, Michaela, Belau, Antje, Busch, Steffi, Guth, Dagmar, Heinrich, Georg, Kreiss-Sender, Janine, Markmann, Susanne, Olbermann, Andreas, Oskay-Özcelik, Gülten, Schuback, Beatrix, Steinfeld-Birg, Dieter, Quiering, Claudia, Kiss, Ferenc, Kreuzeder, Julia, Nuti, Paolo, Schilling, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629492/
https://www.ncbi.nlm.nih.gov/pubmed/37942358
http://dx.doi.org/10.1055/a-2100-0643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629492/
https://www.ncbi.nlm.nih.gov/pubmed/37942358
http://dx.doi.org/10.1055/a-2100-0643

Ejemplares similares